Gene therapy injection for diabetic macular edema
Part of Eyes & vision clinical trials.
This trial tests a one-time gene therapy injection into the eye for adults with diabetic macular edema (DME), a condition where fluid builds up in the retina and blurs vision. The goal is to reduce the need for frequent eye injections and help maintain vision over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have type 1 or type 2 diabetes
- You have swelling in the center of the retina caused by diabetic macular edema
- Your vision loss is mostly due to this swelling
- You have had a good response to aflibercept (Eylea) injections in the past
- You have not had any prior treatment for diabetic macular edema in the study eye
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new gene therapy called LX111 for diabetic macular edema (DME) that has not improved enough with previous injections. It aims to see if a single treatment can reduce swelling and improve vision.
This trial tests an eye injection called OLN324 for diabetic macular edema, a condition where fluid builds up in the retina and blurs vision. The treatment aims to improve vision and reduce swelling in the eye.
This study tests a treatment for diabetic macular edema (swelling in the back of the eye caused by diabetes) in people who have not had eye injections before. It aims to see if the treatment can improve vision.
This study tests an experimental eye injection (OLN324) for people with diabetic macular edema, a condition where swelling in the back of the eye causes vision loss. The goal is to see if the injection can improve vision.
This trial tests a high-dose version of the drug aflibercept (given as an eye injection) for people with diabetic macular edema who have previously had a vitrectomy surgery. The goal is to see if this higher dose can help reduce swelling and improve vision.
This trial tests whether combining a steroid implant (dexamethasone) with an anti-VEGF injection (aflibercept) works better than the injection alone for people with diabetic macular edema who haven't been treated yet. It aims to improve vision and reduce retinal swelling.
Hear when a new Diabetic Macular Edema (DME) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.